USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Companion Diagnostics Market – Growth Opportunities, Analysis, Forecast, Global, 2022
The Transition To Precision Medicine Is Propelling The Adoption Of Cdx Platforms.,Cdx Companion Diagnostics,Companion Diagnostics Market,Companion Diagnostics Oncology
13-Dec-2022
Global
Technology Research
DA87-01-00-00-00
HC03611-GL-TR_27252
The concept of companion diagnostics (CDx) was developed when researchers realized that even potent drugs only had an efficacy between 25% and 60%, the lowest being in oncology. Therefore, a clinical pharmacogenetic assay became important to distinguish patients more likely to respond to a drug or at a lesser risk of associated adverse pathophysiological effects. CDx help medical professionals make better drug therapy choices for patients.
A CDx assay is an IVD device that provides information regarding the safety, efficacy, and monitoring of a particular therapeutic product for a patient.
A CDx assay combines with a drug to form a drug-diagnostic co-development model. A strong biomarker correlation is responsible for this model's success that preclinical research deduces. A CDx assay undergoes analytical and clinical validation and is useful only if it successfully discriminates between a responder and a non-responder.
This Frost & Sullivan study discusses recent trends in CDx developments and their impact on bolstering precision medicine. The study also analyzes upcoming innovation across nucleic acid-based tests, immunoassays, molecular imaging techniques, and multimodal diagnostics. Furthermore, it explores developments in liquid biopsies, next-generation sequencing (NGS) platforms, fluorescence in-situ hybridization (FISH) techniques, and other genetic analysis tools that aid the discovery and development of novel biomarkers for new CDx products and services. The study also discusses global regulatory aspects and the need to streamline policies for accelerated government approvals.
Key Questions the Study Answers:
How are CDx and therapies co-developed?
What are the regulatory requirements for CDx development?
What are the key partnership and funding trends for CDx technologies?
What are the emerging innovations in CDx technologies?
Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Companion Diagnostics (CDx) Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology
Introduction to CDx
Role of CDx in Precision Medicine
Scope
Segmentation
Growth Drivers
Growth Restraints
CDx and Therapeutics Co-development
CDx and Therapeutics Co-development (continued)
Regulatory Requirements for CDx
Regulatory Requirements for CDx (continued)
Summary of Strategic Pharma and Diagnostic Collaborations
Summary of Strategic Pharma and Diagnostic Collaborations (continued)
Overview of Funding Trends
Overview of Tissue CDx Technologies
Workflow Summary for Using AI in Digital Pathology
US FDA-approved Tissue CDx Applications in Oncology
Emerging CDx Applications in Oncology
CDx Application Landscape for Non-cancer Indications
Emerging Trends for Tissue CDx Use in Non-cancer Indications
Outlook for Tissue CDx Platforms
Overview of Liquid Biopsy Platforms
Overview of Liquid Biopsy Analytes and Isolation Technologies
Comparative Analysis of Tissue and Liquid Biopsies
Snapshot of Liquid Biopsy Applications in Cancer Treatment
Key Biomarkers for Top 3 US FDA-approved Liquid Biopsy Indications
Emerging Clinical Trial Landscape for Liquid Biopsy Platforms
Snapshot of Liquid Biopsy Clinical Trials
Outlook for Liquid Biopsy Platforms
Components of Imaging-based CDx
Advantages of Using Imaging-based CDx
Summary of Trends Driving the Growth of Imaging-based CDx
Small Molecules used for Molecular Imaging-based CDx
Peptides Used for Molecular Imaging-based CDx
Antibodies for Molecular Imaging-based CDx
Emerging Clinical Trial Landscape for Imaging-based CDx
Overview of Imaging-based CDx for Non-oncological Indications
Outlook for Imaging-based CDx Platforms
Analyst Perspectives
Growth Opportunity 1: Tissue Multiplexing and Digital Pathology
Growth Opportunity 1: Tissue Multiplexing and Digital Pathology (continued)
Growth Opportunity 2: NGS-based Liquid Biopsy
Growth Opportunity 2: NGS-based Liquid Biopsy (continued)
Growth Opportunity 3: Hybrid Imaging-based CDx
Growth Opportunity 3: Hybrid Imaging-based CDx (continued)
Your Next Steps
Why Frost, Why Now?
Legal Disclaimer
Speak directly with our analytics experts for tailored recommendations.
Recent related Healthcare research
28 Oct 2026 | Global | Frost Radar
Frost Radar™: Health Monitoring Wearable Solutions, 2026
The health monitoring wearables industry is undergoing a profound transformation as competitive advantage shifts from device hardware to integrated digital health ecosystems. Market leaders are differentiating through clinically validated health insights, longitudinal data platforms, AI-enabled anal...
26 Oct 2026 | Global | Technology Research
Game-Changing Innovations Transforming Cardiovascular Care
The study analyzes game-changing technologies transforming cardiovascular care across diagnosis, image-guided intervention, functional assessment, clinical workflow, and longitudinal patient monitoring. The analysis covers five segments: diagnostic imaging and AI-enabled cardiac assessment; interven...
23 Oct 2026 | Global | Technology Research
Innovations and Growth Opportunities in Advanced Medical Devices, Implantable and Diagnostic Solutions
The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) spotlights a diverse slate of innovations across advanced medical devices, diagnostic solutions, and implantable.The issue features advanced medical devices such as single-breath-hold radiotherapy system, transcatheter system f...
16 Oct 2026 | Global | Market Research
Public Sector Healthcare Cloud Market, North America and Europe, 2026
Public healthcare organizations across North America and Europe are using cloud technologies to support modernization efforts that extend beyond infrastructure replacement. Cloud is increasingly being adopted to improve interoperability, enable secure data sharing, support analytics and AI initiativ...
16 Oct 2026 | Global | Technology Research
Innovations and Growth Opportunities in Precision Therapeutics, AI-Enabled Discovery and Bioengineering, Regenerative Medicine, and Next-Generation Vaccine Platforms
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations transforming precision therapeutics, regenerative medicine, AI-enabled discovery, laboratory automation, targeted delivery, vaccines, and biomanufactu...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.